NOVACYT PARTNERS WITH APPLIED MICROARRAYS IN ASSAY DESIGN

US partnership to facilitate the design and optimisation for customised microarray assays

Paris, France and Camberley, UK – 13 September 2018 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, today announces its molecular testing division, Primerdesign Ltd. (Primerdesign), has partnered with Applied Microarrays, Inc. (AMI), a company that specialises in providing customised microarrays and manufacturing point-of-care (POC) and high throughput DNA and protein arrays, to offer comprehensive single nucleotide polymorphism (SNP) assay development. **Primerdesign will play an integral part in designing probes for AMI and their customers. The microarray based molecular diagnostic tests developed under this partnership will play a crucial role in the early diagnosis, as well as improve patient management and outcome. Primerdesign has thirteen years' experience in molecular assay design and this partnership highlights the division's pivotal role in assay development as it grows its relationships with leading diagnostic companies.** Working together, Primerdesign and AMI can provide a full suite of assay development services from probe designs, through to assay optimisation, regulatory and ultimately high volume manufacturing of SNP microarrays for use in POC as well as laboratory-based settings. Alastair Malcolm, President & CEO of AMI, commented:

> "Novacyt is an expert in molecular diagnostic assay design and development and I am pleased to enter this strategic partnership to develop customised microarray based diagnostic tests. Through working with Primerdesign, we have been impressed with their assay development expertise and ability to deliver a high quality service in a timely manner. I am confident that our partnership will help us to deliver multiplexed probe based diagnostic and detection with better diagnosis and improved patient outcomes."

Graham Mullis, Group CEO of Novacyt, added:

> "I am delighted that we are entering into a partnership with AMI. This partnership significantly expands our offering and geographic reach as we continue to expand our molecular products business. "I am also pleased to see continued progress in our business-to-business opportunities converting into commercial partnerships. We are increasingly becoming the partner of choice for molecular diagnostic companies and I look forward to updating shareholders with further partnerships like this."

Financial terms of the agreement have not been disclosed.

Contacts

Novacyt SA Graham Mullis, Chief Executive Officer Anthony Dyer, Chief Financial Officer +44 (0)1223 395472 Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker) Jonathan Senior / Fred Walsh / Ben Maddison +44 (0)20 7610 7600 WG Partners (Joint Broker) Nigel Birks / Chris Lee / Claes Spång +44 (0) 203 705 9330 FTI Consulting (International) Brett Pollard / Victoria Foster Mitchell +44 (0)20 3727 1000 brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com FTI Consulting (France) Arnaud de Cheffontaines / Astrid Villette +33 (0)147 03 69 47 / +33 (0)147 03 69 51 arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com **About Novacyt Group** The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates. For more information please visit: **www.novacyt.com** About **Applied Microarrays** AMI is a

company headquartered in Tempe, AZ, which designs, optimises and manufactures DNA and protein biosensors, and other microarrays on glass, plastic and semiconductors. AMI operates under ISO 9001 and ISO 13485 certification. Since acquiring GE Healthcare's microarray business in 2007, AMI has evolved to become a full service provider for RUO and Dx devices. For more information please visit: www.appliedmicroarrays.com